Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
72
resultados
Última actualización
27/09/2024 [06:45:00]
Resultados 50 a 72 de 72
Resumen de: US2024294639A1
The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
Resumen de: US2024294633A1
Antibodies against human B cell lymphoma 6 protein (BCL-6) are provided. The antibodies have neutralizing activity against BCL-6. The anti-human B cell lymphoma 6 protein antibodies may be used in therapeutic treatment in patients with angiogenesis-dependent conditions.
Resumen de: US2024294666A1
The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.
Resumen de: US2024294599A1
The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target a G-protein coupled receptor (e.g., a G-protein coupled receptor family C group 5 member D (GPRC5D)), and immunoresponsive cells comprising such CARs. The presently disclosed CARs targeting a G-protein coupled receptor (e.g., GPRC5D) have enhanced immune-activating properties, including anti-tumor activity.
Resumen de: US2024293418A1
The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount. Preferably, the first agent comprises an EZH2 inhibitor. In certain embodiments, the first agent is tazemetostat or a pharmaceutically acceptable salt thereof and the methods of the disclosure are used to treat multiple myeloma or mantle cell lymphoma.
Resumen de: US2024294602A1
A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB
Resumen de: US2024294536A1
A pharmaceutical composition comprising a compound and/or a pharmaceutically acceptable salt thereof having the following Formula I is disclosed:wherein R1, R2, R3, and R4 are as defined herein. Also, a method of treating an individual suffering from multiple myeloma, leukemia or lymphoma and method of preparing a compound of Formula I are disclosed. These compounds can be PIKfyve kinase inhibitors.
Resumen de: EP4424822A1
The present invention relates to a nucleic acid encoding a recombinase capable of recombining asymmetric target sequences of SEQ ID NO:1 within the long terminal repeat of proviral DNA of a plurality of HTLV-1 strains, the recombinase having specific amino acid exchanges compared to the sequence of cre recombinase. The invention also provides expression vectors comprising said nucleic acids and cells comprising the same, the recombinase in protein form and pharmaceutical compositions comprising them. A method for provision of such recombinases is also provided. The invention also provides a method of treating a HTLV-1-infected subject, wherein the subject optionally has adult T-cell leukemia (ATL) and/or HTLV-1-associated myelopathy (HAM).
Resumen de: AU2023214116A1
Provided are methods of clinical treatment of Diffuse Large B-cell Lymphoma (for example, relapsed and/or refractory Diffuse Large B-cell Lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with lenalidomide or ibrutinib and lenalidomide.
Resumen de: AU2023213099A1
Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone).
Resumen de: US2024285773A1
Methods of monitoring therapeutic efficacy in a subject with myelodysplastic syndrome (MDS) are provided. Also provided is a method of identifying a subject with MDS for treatment with a telomerase inhibitor, and methods of treating MDS. The methods include administering to the subject a telomerase inhibitor and assessing variant allele frequency (VAF) for one or more of the following genes: SF3B1, TET2, DNMT3A, ASXL1, and CUX1 in a biological sample obtained from the subject after administration of the telomerase inhibitor. In some cases, a 25% or more reduction in VAF identifies a subject who has an increased likelihood of benefiting from treatment with a telomerase inhibitor. In some instances, the telomerase inhibitor is imetelstat or imetelstat sodium.
Resumen de: US2024285624A1
The present disclosure relates generally to the use of an ERK1/2 inhibitor or a SHP2 inhibitor in combination with a FLT3 inhibitor, such as gilteritinib, for treating cancer, specifically acute myeloid leukemia (AML).
Resumen de: US2024285592A1
Human therapeutic treatment compositions comprising a curcumin component, a harmine component, and an isovanillin component, preferably all three in combination. The agents are synergistically effective for treatment of human conditions, especially human cancers, such as brain or central nervous system lymphomas or tumors.
Resumen de: US2024287182A1
This invention relates to methods and compositions for use in treating cancer in a subject. For example, the invention relates to methods and compositions for use in treating esophageal cancer or colorectal cancer (CRC) (e.g., metastatic CRC (e.g., microsatellite instability (MSI) high (MSI-H) metastatic CRC)) in a subject by administering to the subject an anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antagonist antibody (e.g., tiragolumab) and a PD-1 axis binding antagonist (e.g., atezolizumab); methods and compositions for use in treating metastatic CRC (e.g., MSI-H metastatic CRC) in a subject by administering to the subject an anti-TIGIT antagonist antibody (e.g., tiragolumab), a PD-1 axis binding antagonist (e.g., atezolizumab), and an anti-VEGF antibody (e.g., bevacizumab); methods and compositions for use in treating melanoma in a subject by administering to the subject a bispecific antibody targeting programmed cell death protein 1 (PD-1) and lymphocyte activation gene-3 (LAG3), optionally with an anti-TIGIT antagonist antibody (e.g., tiragolumab); and methods and compositions for use in treating a CD20-positive cell proliferative disorder (e.g., non-Hodgkin's lymphoma (NHL); e.g., relapsed or refractory NHL) in a subject by administering to the subject a bispecific antibody targeting CD20 and CD3 (mosunetuzumab) and an anti-TIGIT antagonist antibody (e.g., tiragolumab), optionally with a PD-1 axis binding antagonist (e.g., atezolizumab).
Resumen de: US2024287062A1
The present disclosure relates to compounds and compositions for inhibition of RAF serine/threonine protein kinases and inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as melanoma, non-small cell lung cancer, and chronic myeloid leukemia (CML).
Resumen de: AU2023224879A1
The present invention is directed to compounds of Formula (I), characterized as PROTACs of MALT1. The PROTACs described herein can be useful in the treatment of diseases or disorders associated with MALT1, such as lymphoma. In particular, the invention is concerned with compounds and pharmaceutical compositions capable of degrading MALT1, methods of treating diseases or disorders associated with MALT1, and methods of synthesizing these compounds. (I)
Resumen de: WO2024175803A1
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of myeloid disorders, such as acute myeloid leukemia (AML), in subjects having at least one chromosome abnormality of 3q21 and/or 3q26.
Resumen de: WO2024175887A1
The invention relates to methods of using saRNAs targeting C/EBPα and pharmaceutical compositions comprising the saRNAs to treat diseases such as cancer including acute myeloid leukemia (AML).
Resumen de: WO2024178339A2
Provided herein are methods for treating neuroblastoma characterized as having genetic aberrations in ALK, FAK, and/or MYCN with ESK440.
Resumen de: WO2024178305A1
The present disclosure provides mRNAs encoding an IL- 15 fusion protein comprising an IL- 15 polypeptide, an IL-15Rα polypeptide, and half-life extending moiety and methods of treating cancer, including solid tumors and disseminated cancers such as myeloid malignancies (e.g., multiple myeloma), using the mRNAs described herein, optionally formulated as lipid nanoparticles.
Resumen de: EP4420683A1
It is an object to provide an antibody specifically binding to CD37-positive tumor cells such as malignant B-cell lymphoma, an antibody-drug conjugate comprising the antibody, a pharmaceutical composition having therapeutic effects on a tumor using the antibody, a method for treating a tumor using the aforementioned pharmaceutical composition, a method for producing the antibody, and a method for producing the antibody-drug conjugate, and the like. The present invention provides an anti-CD37 antibody-drug conjugate in which an antibody is conjugated to a drug linker represented by the following formula (wherein A represents a connecting position to the antibody) by a thioether bond, specifically, a humanized anti-CD37 antibody having internalization ability and an antibody-drug conjugate containing the antibody.
Nº publicación: EP4419106A1 28/08/2024
Solicitante:
HANMI PHARMACEUTICAL CO LTD [KR]
Hanmi Pharm. Co., Ltd
Resumen de: TW202329969A
This invention relates to pharmaceutical compositions, pharmaceutical combinations and methods for the treatment of acute myeloid leukemia by combined use of a therapeutically effective combination of a compound of Chemical Formula 1, or a pharmaceutically acceptable salt thereof, solvate thereof, stereoisomer thereof, tautomer thereof, or combination thereof, wherein Ea, Eb, Ec, Ed, Z', X', Q, and k are defined herein; and a Bcl-2 inhibitor, or a Bcl-2 inhibitor and a hypomethylating agent.
BOPI
Sede Electrónica
